FDA Completes Bioresearch Monitoring Inspection of Pz-Cel for Recessive Dystrophic Epidermolysis Bullosa : vimarsana.com

This announcement is part of the overall evaluation period for the treatment, as the PDUFA target action date for pz-cel remains May 2024.

Related Keywords

Cleveland , Ohio , United States , , Abeona Therapeutics Inc , Advisory Committee , Drug Administration , Bioresearch Monitoring , Biologics License Application , Abeona Therapeutics , Chief Executive Officer , Risk Evaluation , Mitigation Strategies , Rdeb , Recessive , Dystrophic , Epidermolysis Bullosa , Deb , Pz Cel , Fda , Bla ,